Kornitzer Capital Management Inc. KS held its stake in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,000 shares of the company’s stock at the end of the second quarter. Kornitzer Capital Management Inc. KS owned 0.30% of Clearside Biomedical worth $683,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of CLSD. Wells Fargo & Company MN raised its stake in shares of Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after buying an additional 12,800 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Clearside Biomedical by 30.7% in the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after buying an additional 4,527 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of Clearside Biomedical during the first quarter worth approximately $178,000. Highbridge Capital Management LLC acquired a new position in shares of Clearside Biomedical during the first quarter worth approximately $217,000. Finally, Bank of New York Mellon Corp raised its position in shares of Clearside Biomedical by 10.8% in the first quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock worth $277,000 after buying an additional 3,404 shares during the period. Hedge funds and other institutional investors own 49.46% of the company’s stock.
Clearside Biomedical, Inc. (CLSD) traded down 1.14% during midday trading on Friday, reaching $6.95. 54,875 shares of the company’s stock traded hands. The company’s 50-day moving average price is $8.65 and its 200-day moving average price is $8.00. The stock’s market cap is $176.09 million. Clearside Biomedical, Inc. has a 52-week low of $5.44 and a 52-week high of $25.08.
Clearside Biomedical (NASDAQ:CLSD) last posted its earnings results on Wednesday, August 9th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.13. Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The company had revenue of $0.13 million during the quarter. On average, equities analysts predict that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BNB Daily and is owned by of BNB Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/kornitzer-capital-management-inc-ks-holds-stake-in-clearside-biomedical-inc-nasdaqclsd-updated.html.
A number of equities analysts have recently commented on CLSD shares. Cowen and Company reiterated a “buy” rating and set a $15.00 price target on shares of Clearside Biomedical in a report on Thursday, May 11th. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Monday, May 15th. JMP Securities initiated coverage on shares of Clearside Biomedical in a research note on Thursday, May 25th. They set an “outperform” rating and a $21.00 target price for the company. ValuEngine raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Finally, TheStreet downgraded shares of Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Clearside Biomedical currently has an average rating of “Buy” and a consensus price target of $19.00.
In related news, Director Clay Thorp sold 24,500 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $7.57, for a total value of $185,465.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel H. White sold 3,600 shares of the stock in a transaction dated Tuesday, June 13th. The stock was sold at an average price of $7.78, for a total transaction of $28,008.00. Following the completion of the transaction, the chief executive officer now owns 504,067 shares of the company’s stock, valued at $3,921,641.26. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 8,200 shares of company stock valued at $58,970 and sold 57,200 shares valued at $465,827. 20.90% of the stock is owned by company insiders.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.